Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NimoBenSeq in Head and Neck Squamous Cell Carcinoma
NCT07535567Phase 3Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of benmelstobart in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Disease-Free Survival at 3 years. Planned start May 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07535567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535567.